Journal of Clinical Immunology

, Volume 30, Supplement 1, pp 43–49 | Cite as

Immunological Origin and Functional Properties of Catalytic Autoantibodies to Amyloid β Peptide

  • Sudhir Paul
  • Stephanie Planque
  • Yasuhiro Nishiyama



Objectives The objectives of this study are to (1) evaluate the ability of the immune system to synthesize specific antibodies that catalyze the degradation of amyloid β peptide (Aβ) and to (2) evaluate the prospect of developing a catalytic IVIG (CIVIG) formulation for therapy of Alzheimer’s disease (AD).


Polyclonal autoantibodies from humans without dementia hydrolyzed Aβ specifically. The catalytic activity improved as a function of age. Patients with AD produced catalytic antibodies at increased levels. IgM-class antibodies expressed the activity at levels superior to IgGs. Production of catalytic autoantibodies appears to be an innate immunity function with adaptive improvements occurring upon Aβ overexpression, which suggests a beneficial function of the catalytic activity. The catalytic autoantibodies impeded Aβ aggregation, dissolved preformed Aβ aggregates, and inhibited Aβ cytotoxicity in tissue culture. Recombinant catalytic antibodies from a human library have been identified, validating the phenomenon of antibody-catalyzed Aβ cleavage. As a single catalyst molecule inactivates multiple Aβ molecules, catalytic antibodies may clear Aβ efficiently. IVIG did not cleave Aβ, indicating the importance of purification procedures that maintain catalytic site integrity. Traditional Aβ-binding antibodies form immune complexes that can induce inflammatory reaction and vascular dysfunction. Catalysts do not form stable immune complexes, minimizing these risks. Criteria appropriate for developing a CIVIG formulation with potential therapeutic utility are discussed, including isolation of the Aβ-specific catalytic subsets present in IgM and IgG from human blood.


Catalytic antibody amyloid β peptide Alzheimer’s disease immunotherapy 



This work was supported by the US National Institutes of Health (1R01AG025304). We thank the co-authors listed in our previous publications for their collaborations.


  1. 1.
    Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev. 2008;7:440–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science. 1989;244:1158–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Paul S, Nishiyama Y, Planque S, Taguchi H. Theory of proteolytic antibody occurrence. Immunol Lett. 2006;103:8–16.CrossRefPubMedGoogle Scholar
  4. 4.
    Paul S, Nishiyama Y, Planque S, Karle S, Taguchi H, Hanson C, et al. Antibodies as defensive enzymes. Springer Semin Immunopathol. 2005;26:485–503.CrossRefPubMedGoogle Scholar
  5. 5.
    Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiyama Y, et al. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection. AIDS Res Hum Retroviruses. 2007;23:1541–54.CrossRefPubMedGoogle Scholar
  6. 6.
    Walsh DM, Selkoe DJ. Aβ oligomers—a decade of discovery. J Neurochem. 2007;101:1172–84.CrossRefPubMedGoogle Scholar
  7. 7.
    Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175–93.CrossRefPubMedGoogle Scholar
  8. 8.
    Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid β peptide. Autoimmun Rev. 2008;7:415–20.CrossRefPubMedGoogle Scholar
  9. 9.
    O'Nuallain B, Acero L, Williams AD, Koeppen HP, Weber A, Schwarz HP, et al. Human plasma contains cross-reactive Aβ conformer-specific IgG antibodies. Biochemistry. 2008;47:12254–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, et al. Catalytic antibodies to amyloid β peptide in defense against Alzheimer’s disease. Autoimmun Rev. 2008;7:391–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, et al. Autoantibody-catalyzed hydrolysis of amyloid β peptide. J Biol Chem. 2008;283:4714–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Qahwash IM, Boire A, Lanning J, Krausz T, Pytel P, Meredith SC. Site-specific effects of peptide lipidation on β-amyloid aggregation and cytotoxicity. J Biol Chem. 2007;282:36987–97.CrossRefPubMedGoogle Scholar
  13. 13.
    Munch G, Mayer S, Michaelis J, Hipkiss AR, Riederer P, Muller R, et al. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of β-amyloid peptide. Biochim Biophys Acta. 1997;1360:17–29.PubMedGoogle Scholar
  14. 14.
    Adekar SP, Klyubin I, Macy S, Rowan MJ, Solomon A, Dessain SK, et al. Inherent anti-amyloidogenic activity of human Ig γ heavy chains. J Biol Chem. 2009. doi: 10.1074/jbc.M109.044321.PubMedGoogle Scholar
  15. 15.
    Silverman GJ, Goodyear CS. Confounding B-cell defenses: lessons from a staphylococcal superantigen. Nat Rev Immunol. 2006;6:465–75.CrossRefPubMedGoogle Scholar
  16. 16.
    Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, et al. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem. 2003;278:20429–35.CrossRefPubMedGoogle Scholar
  17. 17.
    Durova OM, Vorobiev II, Smirnov IV, Reshetnyak AV, Telegin GB, Shamborant OG, et al. Strategies for induction of catalytic antibodies toward HIV-1 glycoprotein gp120 in autoimmune prone mice. Mol Immunol. 2009;47:87–95.CrossRefPubMedGoogle Scholar
  18. 18.
    Li Q, Gordon M, Cao C, Ugen K, Morgan D. Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Aβ antibodies. BMC Neurosci. 2007;8:22.CrossRefPubMedGoogle Scholar
  19. 19.
    Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, et al. Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Aβ and RAGE peptides. Neurobiol Aging. 2004;25:1023–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer’s disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol. 2002;37:943–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res. 2006;84:434–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer’s disease. Neurobiol Aging. 2009;30:1728–36.CrossRefPubMedGoogle Scholar
  23. 23.
    Bacher M, Depboylu C, Du Y, Noelker C, Oertel WH, Behr T, et al. Peripheral and central biodistribution of (111)In-labeled anti-β-amyloid autoantibodies in a transgenic mouse model of Alzheimer’s disease. Neurosci Lett. 2009;449:240–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Mitsuda Y, Planque S, Hara M, Kyle R, Taguchi H, Nishiyama Y, et al. Naturally occurring catalytic antibodies: evidence for preferred development of the catalytic function in IgA class antibodies. Mol Biotechnol. 2007;36:113–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Taguchi H, Planque S, Sapparapu G, Boivin S, Hara M, Nishiyama Y, et al. Exceptional amyloid β peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem. 2008;283:36724–33.CrossRefPubMedGoogle Scholar
  26. 26.
    St-Amour I, Laroche A, Bazin R, Lemieux R. Activation of cryptic IgG reactive with BAFF, amyloid β peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins. Clin Immunol. 2009;133:52–60.CrossRefPubMedGoogle Scholar
  27. 27.
    Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115–29.CrossRefPubMedGoogle Scholar
  28. 28.
    Lacroix-Desmazes S, Bayry J, Kaveri SV, Hayon-Sonsino D, Thorenoor N, Charpentier J, et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci USA. 2005;102:4109–13.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Sudhir Paul
    • 1
  • Stephanie Planque
    • 1
  • Yasuhiro Nishiyama
    • 1
  1. 1.Department of Pathology and Laboratory Medicine, Chemical Immunology Research CenterUniversity of Texas-Houston Medical SchoolHoustonUSA

Personalised recommendations